SNMMI 2023

Viewing 1-20 of 25 articles

SNMMI 2023: PSMA PET Prognostic Value for Outcome of Pre-Chemotherapy Post-ARSI CRPC Patients: A Single Center Retrospective Analysis

SNMMI 2023: 68Ga-PSMA PET/CT-Based Multivariate Model for Highly Accurate and Noninvasive Diagnosis of Clinically Significant Prostate Cancer in the PSA Gray Zone

SNMMI 2023: Intraindividual Comparison of [68Ga]Ga-RM2 and [68Ga]Ga-PSMA PET/CT in Patients with mCRPC in a Theranostic Setting

SNMMI 2023: Tumour-to-Kidney Ratio on Pre-Therapeutic PSMA-PET-CT May Be Predictive of the Response [Of Lymphatic and Bone Metastases] to Therapy in mCRPC

SNMMI 2023: Personalized PSMA-Directed Molecular RT with Identification of Favorable Genomic and Post-Therapeutic Radiomic Parameters: A Real-World Experience Post-FDA-Approval of Lu-177 PSMA-617 from a Single Comprehensive U.S. Theranostic Center

SNMMI 2023: Safety and Efficacy of 177Lu-PSMA-I&T Radioligand Therapy in Octogenarians with mCRPC: Report on 80 Patients over Age of 80

SNMMI 2023: Higher SUV Mean in Baseline 18F-PSMA 1007 PET Is Associated with Longer Survival in Patients Undergoing Radioligand Therapy with [177Lu]Lu-PSMA I&T

SNMMI 2023: PSMA PET/CT for Prostate Cancer Patients After Focal Therapy: A Single Center Retrospective Analysis

SNMMI 2023: Early Adverse Events, Emergency Room Visits and Hospitalizations After PSMA Based RLT: a Retrospective Analysis from Real World Theranostics Practice

SNMMI 2023: Associations Between Antihormonal-Treatment Status and ⁶⁸Ga-PSMA-HBED-CC PET Biodistribution

SNMMI 2023: 89Zr-DFO-Girentuximab PET/CT Imaging Can Accurately Detect Clear Cell Renal Cell Carcinoma Primary and Secondary Lesions in Patients with Renal Masses at Conventional Imaging, Results from ZIRCON Phase 3 Study

SNMMI 2023: Zirconium-Labelled Girentuximab (89Zr-TLX250-CDx) PET/CT Imaging for Non-Invasive Diagnosis of Clear Cell Renal Cell Carcinoma: Results from the UCLA Cohort of the ZIRCON Trial

SNMMI 2023: Comparison of 68Ga-PSMA and 18F-FDG PET/CT in Metastatic Workup of Renal Cell Carcinoma (RCC)

SNMMI 2023: Early Response Assessment to Tyrosine Kinase Inhibitors in Metastatic Clear Cell Cancer Using 68Ga-PSMA-11 PET and CECT: A Comparison Study

SNMMI 2023: PET Evaluation of Changes in c-MET Expression in Metastatic Renal Cell Carcinoma Under Therapy with Cabozantinib

SNMMI 2023: Post-Hoc Analysis of the LIGHTHOUSE and SPOTLIGHT Studies to Assess the Impact of Urinary Activity on Interpretation of 18F-rhPSMA-7.3 PET/CT

SNMMI 2023: Phase I/II Clinical Trial of 177Lu-DGUL in mCRPC Patients: Preliminary Results of Safety, Dosimetry, and Efficacy

SNMMI 2023: Predictive Features of 18F-DCFPyL PSMA PET/MRI in High-Risk Prostate Cancer Patients Treated with Neoadjuvant Chemohormonal Therapy Prior to Radical Prostatectomy

SNMMI 2023: Re-SPECT: Patient Outcomes Following a Response Biomarker Guided Approach to Treatment Using 177Lu-PSMA-I&T in Men with mCRPC

SNMMI 2023: Dual PSMA/FDG PET/CT for Assessing Eligibility and Predicting Response in mCRPC Patients Undergoing 177Lu-PSMA-617 Radioligand Therapy: A Post-VISION Analysis

1
2